Press Releases - 2020-06-11

Date	Title	Company
11-Jun-2020	Orgenesis announces anti-viral “BioShield” program designed to potentially increase preparedness, rapidly address virus spread and protect against future outbreaks such as COVID-19	Orgenesis
11-Jun-2020	Pierre Fabre receives European Commission Marketing Authorisation for BRAFTOVI® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy	Pierre Fabre
11-Jun-2020	ERT Acquires APDM Wearable Technologies to Reinvent Endpoint Measurement in Clinical Trials	ERT
11-Jun-2020	Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation	Ashvattha Therapeutics
11-Jun-2020	Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases	Dupixent
11-Jun-2020	Faron selected for €2.5 million grant from European Innovation Council Accelerator pilot for MATINS study acceleration	Faron Pharmaceuticals Oy
11-Jun-2020	Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing	The European Investment Bank
11-Jun-2020	N95 Mask Market due to Pandemic is Likely to Create Short-term Opportunities for Manufacturers	Regal Intelligence
11-Jun-2020	Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure	BIOPHYTIS
11-Jun-2020	Ethos, a new company, launched to re-define compliance training in a digital age	Ethos Pharmaceutical Ethics and Compliance Limited
11-Jun-2020	Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation	Quell Therapeutics
11-Jun-2020	Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020	Bone Therapeutics
11-Jun-2020	Zelluna Immunotherapy raises funds to fully focus on developing allogeneic “off-the-shelf” TCR based Natural Killer (TCR-NK) cell therapies	About Zelluna Immunotherapy
11-Jun-2020	Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in The New England Journal of Medicine	Alnylam Pharmaceuticals, Inc.
11-Jun-2020	Sygnature Discovery assists New York Medical College in the fight against Covid-19	Sygnature Discovery
11-Jun-2020	Bold Therapeutics Expands COVID-19 Consortium	Bold Therapeutics Inc.
11-Jun-2020	AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute	AVM Biotechnology, LLC
11-Jun-2020	Thalassaemia International Federation and Hemanext® Inc. Announce New Strategic Alliance	Hemanext
11-Jun-2020	(Covid-19) Impact Analysis : Allergic Rhinitis Drugs Market Size, Trends, Analysis, Demand, Outlook and Forecast to 2026	Qurate Business Intelligence
11-Jun-2020	Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress	Rigel Pharmaceuticals, Inc.